ALMR (Alamar Biosciences) Debt-to-Asset : 0.13 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALMR Alamar Biosciences Inc ALMR
12 GF Score
Price $34.85
! 1 Warning Sign
View Full Analysis

What is Alamar Biosciences Debt-to-Asset?

Alamar Biosciences ALMR +8.84% 12 Debt-to-Asset is 0.13 as of Jun. 2026. GuruFocus rates ALMR with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Alamar Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $2.28 Mil. Alamar Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $49.13 Mil. Alamar Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $390.98 Mil. Alamar Biosciences's debt to asset for the quarter that ended in Jun. 2026 was 0.13.

Alamar Biosciences  (NAS:ALMR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Alamar Biosciences Debt-to-Asset Related Terms

Alamar Biosciences Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Alamar Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alamar Biosciences Debt-to-Asset Chart

Alamar Biosciences Annual Data
Trend Dec24 Dec25
Debt-to-Asset
1.79 1.98

Alamar Biosciences Quarterly Data
Mar25 Jun25 Mar26 Jun26
Debt-to-Asset - - 1.83 0.13

ALMR vs ESTA, NVCR, BFLY: Debt-to-Asset Comparison

For the Medical Devices subindustry, Alamar Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alamar Biosciences Debt-to-Asset vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Alamar Biosciences's Debt-to-Asset falls into.


ALMR
12GF Score
Alamar Biosciences Inc ALMR
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alamar Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Alamar Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(2.099 + 274.37) / 139.992
=1.97

Alamar Biosciences's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(2.277 + 49.129) / 390.975
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.13 mean?
Alamar Biosciences (ALMR) has a Debt-to-Asset of 0.13 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Alamar Biosciences and its competitors.
Is Alamar Biosciences' Debt-to-Asset too high?
Alamar Biosciences' current Debt-to-Asset is 0.13. Overall, Alamar Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Debt-to-Asset compare to ESTA and NVCR?
Alamar Biosciences' Debt-to-Asset of 0.13 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Devices & Instruments company?
A good Debt-to-Asset depends on the Medical Devices & Instruments industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Alamar Biosciences and its competitors. Alamar Biosciences's current Debt-to-Asset is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Debt-to-Asset of 0.13. The current Debt-to-Asset is 0.13. Alamar Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Debt-to-Asset is 0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alamar Biosciences Business Description

Address 47071 Bayside Parkway, Fremont, CA, USA, 94538
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
12GF Score

Get the complete analysis for ALMR

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.85
Price